Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associ...
Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis
About this item
Full title
Author / Creator
Wang, Pengfei , Zhang, Li , Guo, Qian , Zhao, Lifen and Hao, Yanyan
Publisher
Warsaw: De Gruyter
Journal title
Language
English
Formats
Publication information
Publisher
Warsaw: De Gruyter
Subjects
More information
Scope and Contents
Contents
The decision for definitive therapy for the treatment of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD) is difficult. Patients with CTD-ILD received 0.5 g twice a day of mycophenolate mofetil for 2 years (MMF cohort,
= 105) or cyclophosphamide 50 mg once every other day, and the cumulative dose of cyclopho...
Alternative Titles
Full title
Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a590c552890e426c89c54ec4023f6ddd
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a590c552890e426c89c54ec4023f6ddd
Other Identifiers
ISSN
2391-5463
E-ISSN
2391-5463
DOI
10.1515/med-2023-0838
